

Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) (1A11) rabbit mAb

www.abwizbio.com

Support: info@abwizbio.com

Order: sales@abwizbio.com

#2066

Store at: -20°C

For Research Use Only. Not For Use In Diagnostic Procedures.

Applications	Detection	Clonality	Isotype
Flow Cytometry, WB	Anti-Rabbit IgG	Monoclonal	Rabbit IgGk

Format: Unconjugated

Cross Reactivity: Predicted to work with mouse, rat, and other homologues.

Formulation: 1X PBS, 0.02% NaN₃, 50% Glycerol, 0.1% BSA

Preparation: Protein A+G

Reactivity: Human, Mouse

Recommended

Usage: 1µg/mL ? 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.


Immunogen: A synthetic phospho-peptide corresponding to residues surrounding Tyr458 of human phospho PI3K p85

Description: Phosphoinositidine 3-kinase (PI3K) targets phosphoinositide lipids for phosphorylation at the D-3 position to serve as a second messenger molecule to activate signaling pathways in response to extracellular stimuli. Akt/protein kinase B (PKB) is a major downstream target of PI3K. The multiple forms of PI3K have different specificities and different affinities for various phosphatidylinositol forms. The PH domains of downstream proteins in these pathways bind to these secondary messengers, causing altered cellular distribution and subsequent kinase activation. The PI3K/Akt pathway is altered in a large proportion of human cancers, as this pathway regulates cellular survival, cell cycle progression, and cell growth.


References:

Franke TF, Kaplan DR, and Cantley LC. (1997) Cell. 88: 435-437.

Fresno JAV, Casado E, Cejas P, et al. (2004) Cancer Treatment Reviews. 30: 193-204.




Flow cytometric analysis of Ramos cells secondary antibody only negative control (blue) or untreated (red) or treated with pervanadate (green) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11. Cat.#2066.




Peptide blocking flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (light blue) or treated with imatinib (red) or with pervanadate (green) or imatinib and blocked with phospho-peptide (black) or pervanadate and blocked with phospho peptide (gold) or imatinib and blocked with non-phospho peptide (dark blue) or pervanadate and blocked with non-phospho peptide (purple) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11 at 0.1 µg/mL. Cat #2066.

IgG	Treatment	Peptide Block	Median : BL1-A
1A11	Pv	Non-phos	6164
1A11	Imat	Non-phos	768
1A11	Pv	Phos	1466
1A11	Imat	Phos	739
1A11	Pv	-	7727
1A11	Imat	-	754
2' only	Imat	-	703



Flow cytometric analysis of NIH3T3 cells secondary antibody only negative control (blue) or 0.1 µg/mL of isotype control Cat. #2141 (orange) or treated with imatinib (red) or with pervanadate (green) using Phospho-PI3 Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11 at 0.1 µg/mL. Cat #2066.



Western blot analysis of NIH3T3 cell extract, untreated or treated with H₂O₂ using 0.5 ug/mL Phospho-PI3Kinase p85 (Tyr458)/p55 (Tyr199) antibody PI3KY458-1A11. Cat #2066.